Invitro moxifloxacin drug interaction with chemotherapeutics: Implications for retinoblastoma management

Experimental Eye Research

Volumn 118, Issue , 2014, Pages 61-71

  Barot, Megha ^a   Gokulgandhi, Mitan R ^a   Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Anticancer agents; Moxifloxacin; Multidrug resistant (MDR); Retinoblastoma

Indexed keywords

CASPASE 3; ELACRIDAR; ETOPOSIDE; INTERLEUKIN 6; INTERLEUKIN 8; MOXIFLOXACIN; MULTIDRUG RESISTANCE PROTEIN; TOPOTECAN; VERLUKAST; VINBLASTINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ACTIVITY; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; TREATMENT FAILURE; ANTICANCER AGENTS; CHILD; COMPARATIVE STUDY; DRUG INTERACTION; HUMAN; METABOLISM; MULTIDRUG RESISTANT (MDR); PATHOLOGY; RETINA TUMOR; TUMOR CELL LINE; RETINAL NEOPLASMS;

ANTICANCER AGENTS; MOXIFLOXACIN; MULTIDRUG RESISTANT (MDR); RETINOBLASTOMA;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; CELL LINE, TUMOR; CHILD; DRUG INTERACTIONS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; QUINOLINES; RETINAL NEOPLASMS; RETINOBLASTOMA; FLUOROQUINOLONES;

EID: 84890074282     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.10.009     Document Type: Article

References (41)

1. Asbell P.A., Colby K.A., Deng S., McDonnell P., Meisler D.M., Raizman M.B., Sheppard J.D., Sahm D.F. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am. J. Ophthalmol. 2008, 145:951-958.
2. Barot M., Gokulgandhi M.R., Haghnegahdar M., Dalvi P., Mitra A.K. Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells. J. Ocul. Pharmacol. Ther. 2011, 27:553-559.
3. Benitez-Del-Castillo J., Verboven Y., Stroman D., Kodjikian L. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis. Clin. Drug Investig. 2011, 31:543-557.
4. Bertino J.S. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin. Ophthalmol. 2009, 3:507-521.
5. Brew R., Erikson J.S., West D.C., Kinsella A.R., Slavin J., Christmas S.E. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells invitro. Cytokine 2000, 12:78-85.
6. Broaddus E., Topham A., Singh A.D. Incidence of retinoblastoma in the USA: 1975-2004. Br. J. Ophthalmol. 2009, 93:21-23.
7. Bromberg K.D., Burgin A.B., Osheroff N. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Biochemistry 2003, 42:3393-3398.
8. Callegan M.C., Ramirez R., Kane S.T., Cochran D.C., Jensen H. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv. Ther. 2003, 20:246-252.
9. Chan H.S., DeBoer G., Thiessen J.J., Budning A., Kingston J.E., O'Brien J.M., Koren G., Giesbrecht E., Haddad G., Verjee Z., Hungerford J.L., Ling V., Gallie B.L. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin. Cancer Res. 1996, 2:1499-1508.
10. Chan H.S., Lu Y., Grogan T.M., Haddad G., Hipfner D.R., Cole S.P., Deeley R.G., Ling V., Gallie B.L. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res. 1997, 57:2325-2330.
11. Chan H.S., Thorner P.S., Haddad G., Gallie B.L. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology 1991, 98:1425-1431.
12. Chen G., Teicher B.A., Frei E. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Anticancer Res. 1996, 16:3499-3505.
13. Chintagumpala M., Chevez-Barrios P., Paysse E.A., Plon S.E., Hurwitz R. Retinoblastoma: review of current management. Oncologist 2007, 12:1237-1246.
14. Dalhoff A., Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 2003, 3:359-371.
15. Dimaras H., Heon E., Doyle J., Strahlendorf C., Paton K.E., Halliday W., Babyn P., Gallie B.L., Chan H.S. Multifaceted chemotherapy for trilateral retinoblastoma. Arch. Ophthalmol. 2011, 129:362-365.
16. Fabian I., Reuveni D., Levitov A., Halperin D., Priel E., Shalit I. Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br. J. Cancer 2006, 95:1038-1046.
17. Gokulgandhi M.R., Barot M., Bagui M., Pal D., Mitra A.K. Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis. J. Pharm. Sci. 2012, 101:3249-3263.
18. Gruss-Fischer T., Fabian I. Protection by ascorbic acid from denaturation and release of cytochrome c, alteration of mitochondrial membrane potential and activation of multiple caspases induced by H(2)O(2), in human leukemia cells. Biochem. Pharmacol. 2002, 63:1325-1335.
19. Hariharan S., Minocha M., Mishra G.P., Pal D., Krishna R., Mitra A.K. Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. J.Ocul. Pharmacol. Ther. 2009, 25:487-498.
20. Horowitz N.S., Hua J., Gibb R.K., Mutch D.G., Herzog T.J. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an invitro model. Gynecol. Oncol. 2004, 94:67-73.
21. Jain R., Agarwal S., Majumdar S., Zhu X., Pal D., Mitra A.K. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int. J. Pharm. 2005, 303:8-19.
22. Kernt M., Neubauer A.S., Liegl R.G., Lackerbauer C.A., Eibl K.H., Alge C.S., Ulbig M.W. Intracameral moxifloxacin: invitro safety on human ocular cells. Cornea 2009, 28:553-561.
23. Krishnakumar S., Mallikarjuna K., Desai N., Muthialu A., Venkatesan N., Sundaram A., Khetan V., Shanmugam M.P. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br. J. Ophthalmol. 2004, 88:1521-1526.
24. Lee T.W., Yang S.W., Kim C.M., Hong W.S., Youn D.H. Chemosensitization to adriamycin by cyclosporin A and verapamil in human retinoblastoma cell lines. J.Korean Med. Sci. 1993, 8:104-109.
25. McGee D.H., Holt W.F., Kastner P.R., Rice R.L. Safety of moxifloxacin as shown in animal and invitro studies. Surv. Ophthalmol. 2005, 50(Suppl.1):S46-S54.
26. Mizukami Y., Jo W.S., Duerr E.M., Gala M., Li J., Zhang X., Zimmer M.A., Iliopoulos O., Zukerberg L.R., Kohgo Y., Lynch M.P., Rueda B.R., Chung D.C. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005, 11:992-997.
27. Pal D., Mitra A.K. MDR- and CYP3A4-mediated drug-drug interactions. J.Neuroimmune Pharmacol. 2006, 1:323-339.
28. Rautio J., Humphreys J.E., Webster L.O., Balakrishnan A., Keogh J.P., Kunta J.R., Serabjit-Singh C.J., Polli J.W. Invitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab. Dispos 2006, 34:786-792.
29. Reuveni D., Halperin D., Fabian I., Tsarfaty G., Askenasy N., Shalit I. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem. Pharmacol. 2010, 79:1100-1107.
30. Reuveni D., Halperin D., Shalit I., Priel E., Fabian I. Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. Biochem. Pharmacol. 2008, 75:1272-1281.
31. Saravolatz L.D., Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin. Infect. Dis. 2003, 37:1210-1215.
32. Scoper S.V. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Adv. Ther. 2008, 25:979-994.
33. Shalit I., Horev-Azaria L., Fabian I., Blau H., Kariv N., Shechtman I., Alteraz H., Kletter Y. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob. Agents Chemother. 2002, 46:2442-2449.
34. Shalit I., Kletter Y., Halperin D., Waldman D., Vasserman E., Nagler A., Fabian I. Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia. Eur. J. Haematol. 2001, 66:287-296.
35. Shields J.A., Augsburger J.J. Current approaches to the diagnosis and management of retinoblastoma. Surv. Ophthalmol. 1981, 25:347-372.
36. Shields J.A., Shields C.L., Parsons H.M. Differential diagnosis of retinoblastoma. Retina 1991, 11:232-243.
37. Vene R., Arena G., Poggi A., D'Arrigo C., Mormino M., Noonan D.M., Albini A., Tosetti F. Novel cell death pathways induced by N-(4-hydroxyphenyl) retinamide: therapeutic implications. Mol. Cancer Ther. 2007, 6:286-298.
38. Wang Q., Strab R., Kardos P., Ferguson C., Li J., Owen A., Hidalgo I.J. Application and limitation of inhibitors in drug-transporter interactions studies. Int. J. Pharm. 2008, 356:12-18.
39. Weiss T., Shalit I., Blau H., Werber S., Halperin D., Levitov A., Fabian I. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob. Agents Chemother. 2004, 48:1974-1982.
40. Wilson M.W., Fraga C.H., Rodriguez-Galindo C., Hagedorn N., Leggas M.L., Stewart C. Expression of the multi-drug resistance proteins and the pregnane X receptor in treated and untreated retinoblastoma. Curr. Eye Res. 2009, 34:386-394.
41. Wu W.C., Hu D.N., Gao H.X., Chen M., Wang D., Rosen R., McCormick S.A. Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by retinal pigment epithelial cells. Mol. Vis. 2010, 16:1864-1873.